Clinical Trial

Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

Study acronym: DATE-AGING
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-12-07; most recent amendment 2026-06-21.
Status change: Not Yet Recruiting → Recruiting 2025-12-21
Trial Details
NCT Number NCT07294209
Lead Sponsor Southwest Hospital, China
Conditions Acute Ischemic Stroke Patients
Enrollment 798 participants
Start Date 2025-12-19
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23